Cidara Therapeutics, Inc. announced on June 26, 2025, the closing of its underwritten public offering, raising gross proceeds of $402.5 million. This included the full exercise by the underwriters of their option to purchase additional shares.
The offering involved the sale of 9,147,727 shares of common stock at a price to the public of $44.00 per share. All shares in the offering were sold by Cidara.
This significant capital infusion strengthens Cidara's financial position, providing crucial funding for the advancement of its proprietary Cloudbreak platform and its lead drug candidate, CD388, a long-acting antiviral for influenza prevention.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.